Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2012 1
2020 1
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A, Taguchi I, Hisauchi I, Yoshida H, Shimabukuro M, Hongo H, Ishikawa T, Kadokami T, Yagi S, Sata M, Node K; DIANA study investigators. Tanaka A, et al. Eur J Med Res. 2023 Jul 17;28(1):238. doi: 10.1186/s40001-023-01208-1. Eur J Med Res. 2023. PMID: 37461063 Free PMC article.
Simple risk-score model for in-hospital major bleeding based on multiple blood variables in patients with acute myocardial infarction.
Goriki Y, Yoshioka G, Natsuaki M, Shinzato K, Nishihira K, Kuriyama N, Shimomura M, Inoue Y, Nishikido T, Kaneko T, Yokoi K, Yajima A, Sakamoto Y, Tago M, Kawaguchi A, Yamamoto F, Tanaka A, Yamaguchi T, Shiraki A, Asaka M, Kotooka N, Sonoda S, Hikichi Y, Shibata Y, Node K. Goriki Y, et al. Int J Cardiol. 2022 Jan 1;346:1-7. doi: 10.1016/j.ijcard.2021.11.046. Epub 2021 Nov 19. Int J Cardiol. 2022. PMID: 34801614
Serum Albumin and Bleeding Events After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction (from the HAGAKURE-ACS Registry).
Yoshioka G, Natsuaki M, Goriki Y, Shinzato K, Nishihira K, Kuriyama N, Shimomura M, Inoue Y, Nishikido T, Hongo H, Kaneko T, Kamishita K, Yokoi K, Yajima A, Sakamoto Y, Tago M, Kawaguchi A, Yamaguchi T, Asaka M, Kotooka N, Sonoda S, Hikichi Y, Shibata Y, Node K. Yoshioka G, et al. Am J Cardiol. 2022 Feb 15;165:19-26. doi: 10.1016/j.amjcard.2021.10.043. Epub 2021 Dec 7. Am J Cardiol. 2022. PMID: 34893303
Correction to: Influence of CYP2C19 genotypes for the effect of 1‑month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12‑month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT‑2.
Watanabe H, Morimoto T, Ogita M, Suwa S, Natsuaki M, Suematsu N, Koeda Y, Morino Y, Nikaido A, Hata Y, Doi M, Hibi K, Kimura K, Yoda S, Kaneko T, Nishida K, Kawai K, Yamaguchi K, Wakatsuki T, Tonoike N, Yamamoto M, Shimizu S, Shimohama T, Ako J, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. Cardiovasc Interv Ther. 2021 Oct;36(4):416-417. doi: 10.1007/s12928-020-00741-8. Cardiovasc Interv Ther. 2021. PMID: 33580476 No abstract available.
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
Watanabe H, Morimoto T, Ogita M, Suwa S, Natsuaki M, Suematsu N, Koeda Y, Morino Y, Nikaido A, Hata Y, Doi M, Hibi K, Kimura K, Yoda S, Kaneko T, Nishida K, Kawai K, Yamaguchi K, Wakatsuki T, Tonoike N, Yamamoto M, Shimizu S, Shimohama T, Ako J, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. Cardiovasc Interv Ther. 2021 Oct;36(4):403-415. doi: 10.1007/s12928-020-00719-6. Epub 2020 Nov 12. Cardiovasc Interv Ther. 2021. PMID: 33184726
Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H, Kimura K, Simonton CA, Kozuma K; RESET Investigators. Kimura T, et al. Circulation. 2012 Sep 4;126(10):1225-36. doi: 10.1161/CIRCULATIONAHA.112.104059. Epub 2012 Jul 23. Circulation. 2012. PMID: 22824435 Clinical Trial.